Lannett Company News

04/07/15 LANNETT TO PRESENT AT THE 14th ANNUAL NEEDHAM HEALTHCARE CONFERENCE ON APRIL 14th.

Lannett Company, Inc. (NYSE: LCI) today announced that the company's chief executive officer, Arthur Bedrosian, and chief financial officer, Martin Galvan, will present at the 14th Annual Needham Healthcare Conference on Tuesday, April 14, 2015, at 12:10 p.m. ET at The Westin Grand Central Hotel, in New York.
Read More
Listen To Audio Webcast

02/27/15 LANNETT TO PRESENT AT THE 27th ANNUAL ROTH CONFERENCE ON MARCH 9.

Lannett Company, Inc. (NYSE: LCI) today announced that the company will present at the 27th Annual ROTH Conference on Monday, March 9, 2015, at 11:30 a.m. Pacific Time at The Ritz-Carlton, Laguna Niguel, CA.
Read More
Listen To Audio Webcast

02/24/15 Lannett To Present At The RBC Capital Market 2015 Healthcare Conference February 24.

Lannett Company, Inc. (NYSE: LCI) today announced that the company will present at the RBC Capital Market 2015 Healthcare Conference today, February 24, 2015, at 4:35 p.m. Eastern Time at The New York Palace hotel in New York City.
Read More
Listen To Audio Webcast

02/04/15 LANNETT REPORTS RECORD FISCAL 2015 SECOND QUARTER NET SALES OF $115 MILLION, EPS OF $1.21

Lannett Company, Inc. (NYSE: LCI) today reported financial results for its fiscal 2015 second quarter ended December 31, 2014.
Read More
Consolidated Balance Sheets
Listen To Audio Webcast

01/26/15 Lannett Announces Preliminary Fiscal 2015 Second Quarter Net Sales Of Approximately $115 Million, EPS Between $1.18 And $1.21.

Lannett Company, Inc. (NYSE: LCI) today announced that it expects to report fiscal 2015 second quarter net sales of approximately $115 million and diluted earnings per share between $1.18 and $1.21.
Read More
Listen To Audio Webcast

01/05/15 Lannett To Present At The 33rd Annual J.P. Morgan Healthcare Conference On January 14.

Lannett Company, Inc. (NYSE: LCI) today announced that the company will present at the 33rd Annual J.P. Morgan Healthcare Conference on Wednesday, January 14, 2015, at 9:30 a.m. Pacific Standard Time at the Westin St. Francis hotel in San Francisco.
Read More
Listen To Audio Webcast

12/18/14 Lannett Receives FDA Approval for Dorzolamide HCL with Timolol.

Lannett Company, Inc. (NYSE: LCI) today announced that it has received approval from the U.S. Food and Drug Administration (FDA) of its Abbreviated New Drug Application (ANDA) for Dorzolamide Hydrochloride and Timolol Maleate Ophthalmic Solution, 2%/0.5%, the therapeutic equivalent to the reference listed drug, Cosopt® Ophthalmic Solution, 2%/0.5%, of Oak Pharmaceuticals, Inc..
Read More

12/05/14 Lannett Names Michael Bogda As President

Lannett Company, Inc. (NYSE: LCI) today announced the appointment of Michael J. Bogda as president, effective December 1, 2014. Arthur Bedrosian remains the company's chief executive officer. Read More

12/02/14 Lannett To Present At The Oppenheimer 25th Annual Healthcare Conference On December 10.

Lannett Company, Inc. (NYSE: LCI) today announced that the company will present at the Oppenheimer 25th Annual Healthcare Conference on Wednesday, December 10, 2014, at 10:55 a.m. Eastern Standard Time at the Crowne Plaza Times Square Manhattan hotel in New York City.
Read More
Listen To Audio Webcast

11/17/14 Lannett Announces Ernest J. Sabo, the company’s vice president of regulatory affairs and chief compliance officer, will retire.

Lannett Company, Inc. (NYSE: LCI) today announced that Ernest J. Sabo, company’s vice president of regulatory affairs and chief compliance officer, will retire from the company, effective January 2, 2015. Read More

11/03/14 Lannett Reports Net Sales of $93 Million, EPS of $0.94 For Fiscal 2015 First Quarter -- Company Raises Outlook for Fiscal 2015--

Lannett Company, Inc. (NYSE: LCI) today reported financial results for its fiscal 2015 first quarter ended September 30, 2014. For the fiscal 2015 first quarter, net sales doubled to $93.4 million from $45.8 million in last year's first quarter. Read More
Listen To Audio Webcast

11/03/14 Lannett Announces Positive FDA Inspection Results

Lannett Company, Inc. (NYSE: LCI) today announced that the U.S. Food and Drug Administration (FDA) has completed its cGMP compliance inspection of Lannett?s wholly owned subsidiary Cody Laboratories, Inc. (Cody), a manufacturer of active pharmaceutical ingredients (APIs) and finished dosage form products. Read More

10/29/14 LANNETT RECEIVES FDA APPROVAL FOR LETROZOLE TABLETS USP 2.5 MG

Lannett Company, Inc. (NYSE: LCI) today today announced that it has received approval from the U.S. Food and Drug Administration (FDA) of its Abbreviated New Drug Application (ANDA) for Letrozole Tablets USP, 2.5 mg, the therapeutic equivalent to the reference listed drug, Femara? Tablets, 2.5 mg, of Novartis Pharmaceuticals Corporation. Read More

10/29/14 LANNETT TO PRESENT AT THE 2014 CREDIT-SUISSE HEALTHCARE CONFERENCE ON NOV 11

Lannett Company, Inc. (NYSE: LCI) today announced that the company will present at the Credit-Suisse 2014 Healthcare Conference on Tuesday, November 11, 2014, at 4:30 p.m. Mountain Standard Time (6:30 p.m. Eastern Standard Time) at The Biltmore Hotel in Phoenix, AZ. Read More
Listen To Audio Webcast

10/23/14 Lannett Announces Preliminary Fiscal 2015 First Quarter Net Sales Of Approximately $93 Million, EPS Between $0.91 And $0.94 -Company to Report Full Financial Results, Host Conference Call on November 3-

Lannett Company, Inc. (NYSE: LCI) today announced that it expects to report fiscal 2015 first quarter net sales of approximately $93 million and diluted earnings per share between $0.91 and $0.94. Read More
Listen To Audio Webcast

09/30/14 CLASS ACTION LAWSUIT AGAINST LANNETT VOLUNTARILY DISMISSED WITHOUT PREJUDICE

Lannett Company, Inc. (NYSE: LCI) today announced that the class action lawsuit filed against the company and certain officers in the United States District Court for the Eastern District of Pennsylvania, entitled Schaefer v. Lannett Company, Inc., et al., has been voluntarily dismissed without prejudice by the plaintiff. Read More

09/22/14 Lannett Launches Oxycodone Hydrochloride Oral Solution

Lannett Company, Inc. (NYSE: LCI) today announced that it has commenced shipping its recently approved Oxycodone Hydrochloride Oral Solution USP, 100 mg per 5 mL. According to IMS, annualized sales of Oxycodone Hydrochloride Oral Solution USP, 100 mg per 5 mL, at Average Wholesale Price (AWP) were approximately $43 million. Read More

09/16/14 Lannett Voluntarily Conducts Internal Review In Response To Inquiry From Connecticut Attorney General Received in July 2014. --Company Concludes It Is In Compliance With Applicable Laws and Requlations.

Lannett Company, Inc. (NYSE: LCI) today announced that upon receipt of the subpoena from the State of Connecticut Office of the Attorney General it voluntarily engaged outside counsel and other experts to conduct an internal review focusing on the company's pricing practices for digoxin. Read More

09/10/14 Lannett Receives FDA Approval For Oxycodone Hydrochloride Oral Solution USP, 100 MG Per 5 ML

Lannett Company, Inc. (NYSE: LCI) today announced that it has received approval from the U.S. Food and Drug Administration (FDA) of its Abbreviated New Drug Application (ANDA) for Oxycodone Hydrochloride Oral Solution USP, 100 mg per 5 mL, the therapeutic equivalent to the reference listed drug, Oxycodone Hydrochloride Oral Solution USP, 100 mg per 5 mL, of Lehigh Valley Technologies, Inc. Read More

08/28/14 Lannett will present at the Morgan Stanley Global Healthcare Conference 2014 on Monday, September 8, 2014

Lannett Company, Inc. (NYSE: LCI) today announced that the company will present at the Morgan Stanley Global Healthcare Conference 2014 on Monday, September 8, 2014, at 10:30 a.m. Eastern at the Grand Hyatt New York Hotel.
Read More
Listen To Audio Webcast

08/20/14 Lannett today commented on the utilization of Digoxin

Lannett Company, Inc. (NYSE: LCI) today commented on the utilization of Digoxin, following a recently published abstract in the Journal of the American College of Cardiology (JACC), which suggested a potential increased risk of mortality in patients with newly diagnosed atrial fibrillation. The abstract was based on data of the TREAT-AF (The Retrospective Evaluation and Assessment of Therapies in AF) study from the U.S. Department of Veterans Affairs (VA) healthcare system. Read More

08/20/14 Lannett to aquire two generic pharmaceutical Products

Lannett Company, Inc. (NYSE: LCI) today announced that it has agreed to purchase ANDAs for Estradiol Tablets, USP, 0.5 mg, 1 mg and 2 mg, and Selegiline Hydrochloride Capsules 5 mg, upon the completion of a successful technical transfer. The company did not disclose the name of the seller nor the financial terms of the transaction. Read More

08/18/14 Lannett announced that it expects to report fiscal 2014 fourth quarter net sales of approximately $81 million

Lannett Company, Inc. (NYSE: LCI) today announced that it expects to report fiscal 2014 fourth quarter net sales of approximately $81 million and diluted earnings per share attributable to Lannett Company in the range of $0.60 and $0.64.
Read More
Listen To Audio Webcast

08/05/14 Lannett To Present At The Canaccord Genuity 34th Annual Growth Conference On August 13

Lannett Company, Inc. (NYSE: LCI) today announced that the company will present at the Canaccord Genuity 34th Annual Growth Conference on Wednesday, August 13, 2014, at 1:30 p.m. Eastern at the InterContinental Boston Hotel.
Read More
Listen To Audio Webcast

08/04/14 Lannett has received approval from the FDA for Oxycodone Hydrochloride Capsules, 5 mg.

Lannett Company, Inc. (NYSE: LCI)today announced that it has received approval from the U.S. Food and Drug Administration (FDA) of its Abbreviated New Drug Application (ANDA) for Oxycodone Hydrochloride Capsules, 5 mg, the therapeutic equivalent to the reference listed drug, Oxycodone Hydrochloride Capsules, 5 mg, of Lehigh Valley Technologies, Inc. Read More

07/18/14 Lannett has signed an agreement with Symplmed, Inc.

Lannett Company, Inc. (NYSE: LCI) today announced that it has signed an agreement with Symplmed, Inc. to be the exclusive distributor in the United States of an authorized generic version of ACEON? (perindopril erbumine tablets) in 2 mg, 4 mg and 8 mg dosage strengths. Read More

07/16/14 Lannett Receives Inquiry From Connecticut Attorney General

Lannett Company, Inc. (NYSE: LCI) today announced that it has received interrogatories and subpoena from the State of Connecticut Office of the Attorney General concerning its investigation into pricing of digoxin.
Read More

06/16/14 Lannett Receives FDA Approval for Codeine Sulfate Tablets USP

Lannett Company, Inc. (NYSE: LCI) today announced that it has received approval from the U.S. Food and Drug Administration (FDA) of its Abbreviated New Drug Application (ANDA) for Codeine Sulfate Tablets USP, a schedule II controlled substance, 15 mg, 30 mg and 60 mg, the therapeutic equivalent to the reference listed drug, Codeine Sulfate Tablets USP 15 mg, 30 mg and 60 mg, of Roxane Laboratories, Inc.
Read More

06/02/14 Lannett To Be Added To S&P Small CAP 600 Index

Lannett Company, Inc. (NYSE: LCI) today announced that the company will be added to the S&P SmallCap 600 Index today, after the close of trading.
Read More

05/12/14 Lannett Announces Multi-services Agreement with Sunshine Lake LLC, A U.S. Subsidiary of HEC Pharm Group

Lannett Company, Inc. (NYSE: LCI) today announced that it has entered into distribution and contract manufacturing services agreements with Sunshine Lake LLC, the U.S. subsidiary of the HEC Pharm Group (HEC) of Shenzhen, Guangdong Province, China.
Read More




















Lannett Company NEws
Lannett Company News